Mural Oncology plc (MURA)
Automate Your Wheel Strategy on MURA
With Tiblio's Option Bot, you can configure your own wheel strategy including MURA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MURA
- Rev/Share 0.0
- Book/Share 6.2839
- PB 0.3931
- Debt/Equity 0.0629
- CurrentRatio 5.0815
- ROIC -0.9071
- MktCap 42654134.0
- FreeCF/Share -7.4584
- PFCF -0.3331
- PE -0.3244
- Debt/Assets 0.0514
- DivYield 0
- ROE -0.8339
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MURA | Morgan Stanley | Overweight | Equal Weight | -- | -- | March 25, 2025 |
| Downgrade | MURA | Raymond James | Strong Buy | Outperform | -- | $18 | March 25, 2025 |
News
Mural Oncology Announces Number of Relevant Securities in Issue
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass. and DUBLIN, May 19, 2025 (GLOBE NEWSWIRE) -- In accordance with Rule 2.12 of the Irish Takeover Panel Act 1997, the Irish Takeover Rules 2022 (the “Irish Takeover Rules”), Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, (“Mural”) confirms that, as of the close of business on May 1, 2025, the issued share capital of Mural was 17,268,881 ordinary shares with par value US$0.01 each (the “Ordinary Shares”).
Read More
FORM 8.1(a) & (b) - Mural Oncology plc
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1. KEY INFORMATION (a) Full name of discloser: Mural Oncology plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.
Read More
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.
Read More
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis
Read More
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at https://ir.muraloncology.com/events-and-presentations. A replay of the webcast will be archived and available following the event.
Read More
About Mural Oncology plc (MURA)
- IPO Date 2023-11-16
- Website https://www.muraloncology.com
- Industry Biotechnology
- CEO Ms. Caroline J. Loew Ph.D.
- Employees 116